Internship

Business Development Intern

Posted on 12/20/2024

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Biotechnology
Healthcare

San Diego, CA, USA

Requires in-person commitment for a 10-week full-time summer program in San Diego, CA.

Category
Business Development
Business & Strategy

You match the following Neurocrine Biosciences's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Third-year undergraduate student with major in the life sciences (Neuroscience major preferred)
  • Good verbal and written communication skills
  • Ability to think creatively and be a team player
  • Offer flexibility with a willingness to work on multiple projects simultaneously
  • Bring to the Company a skill set complementary to its technology and development therapeutics
  • Ability to commit to a 10-week full-time summer program (in-person in San Diego, CA)
Responsibilities
  • Supporting a range of activities, including deal sourcing as well as product and technology assessment
  • Monitoring industry trends, companies, technologies and therapeutic areas of relevance to Neurocrine
  • Interacting with multiple functional areas within the company such as research, clinical development, and finance
  • Completing a special project and presenting the recommendations to senior management upon completion
Desired Qualifications
  • Market research experience and finance / valuation skills would be an asset but is not required
  • Prior experience in the pharmaceutical or biotechnology industry would be an asset but is not required
  • Familiarity with biopharmaceutical technologies, physical and life sciences, product development, and regulatory approval processes is desirable
  • Interest in attending various program events, including social gatherings, career development workshops, and more
Neurocrine Biosciences

Neurocrine Biosciences

View

Company Stage

IPO

Total Funding

N/A

Headquarters

San Diego, California

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • Crenessity's launch in the US taps into the growing rare disease treatment market.
  • Strategic collaborations with Takeda and Nxera enhance Neurocrine's drug development pipeline.
  • FDA initiatives expedite approval processes, benefiting Neurocrine's first-in-class therapies.

What critics are saying

  • Increased competition in the muscarinic agonist market from companies like Karuna Therapeutics.
  • Global expansion of Crenessity faces regulatory and market access challenges.
  • Reliance on PANTHERx Rare for Crenessity distribution poses supply chain risks.

What makes Neurocrine Biosciences unique

  • Neurocrine's Crenessity is the first non-steroidal treatment for classic congenital adrenal hyperplasia.
  • The company has exclusive worldwide rights to develop osavampator, except in Japan.
  • Neurocrine's muscarinic agonist portfolio targets schizophrenia and dementia with subtype-selective therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Parental Leave

Health Insurance

Dental Insurance

Vision Insurance

Paid Holidays

INACTIVE